CSL Shares Plummet to Lowest Valuation in Half a Decade

CSL Limited’s stock is experiencing a historic downturn, reaching its lowest price point in five years. The biotechnology giant is confronting a combination of disappointing profit forecasts, significant operational headwinds, and a sweeping corporate restructuring initiative.

The immediate catalyst for the recent sell-off was a disappointing fiscal year 2025 forecast. The company now anticipates an adjusted net profit in the range of $3.2 to $3.3 billion USD, falling notably short of market expectations which were set at $3.39 billion. This announcement triggered an immediate drop of over 3% in the share price.

Management cited persistent weakness in its vaccine division, attributed to what it described as “highly irrational” market conditions in the United States, coupled with decelerating growth in... Read more...